Back to Search
Start Over
The Impact of Accelerated HF-rTMS on the Subgenual Anterior Cingulate Cortex in Refractory Unipolar Major Depression: Insights From 18FDG PET Brain Imaging
- Source :
- Brain Stimulation, Vol 8, Iss 4, Pp 808-815 (2015)
- Publication Year :
- 2015
- Publisher :
- Elsevier BV, 2015.
-
Abstract
- Background: Although one of the most frequent diagnosed mental illnesses worldwide, it appears to be challenging to successfully treat major depressive disorder (MDD). Although the phenomenon of treatment-resistant depression (TRD) still remains unclear, the subgenual anterior cingulate cortex (sgACC) has been put forward as a possible neurobiological marker to evaluate clinical effects of a variety of antidepressant treatments, including repetitive transcranial magnetic stimulation (rTMS). Accelerated high-frequency (HF)-rTMS may have the potential to rapidly result in beneficial clinical outcomes in TRD. No studies yet examined the clinical effects of such accelerated stimulation treatment paradigms on sgACC regional glucose metabolism (CMRglc), nor the predictive value of the latter for clinical outcome. Objective: First, we investigated the predictive value of baseline sgACC metabolic activity for clinical outcome. Second, we hypothesized that in clinical responders only accelerated HF-rTMS treatment would result in significant metabolic decreases. Methods: We recruited right-handed antidepressant-free unipolar melancholic TRD patients to participate in a two-week randomized sham-controlled crossover HF-rTMS treatment study. Stimulation was applied to the left dorsolateral prefrontal cortex (DLPFC). Fifteen patients underwent 18FDG PET (CMRglc) at baseline (T0), after the first week (T1) of accelerated HF-rTMS and at the end of the treatment after the second week (T2). Results: Higher baseline sgACC metabolic activity may indicate beneficial clinical outcome to this kind of accelerated HF-rTMS treatment. Moreover, clinical response resulted in a significant decrease in sgACC CMRglc. Non-response did not affect sgACC CMRglc. Conclusions: Our results add to the sgACC as a specific neurobiological marker for anti-depressive response in accelerated HF-rTMS treatment paradigms. Such protocols may not only have the ability to result in fast clinical responses but they may also have potential to acutely modulate a dysfunctional sgACC.
- Subjects :
- Male
medicine.medical_specialty
medicine.medical_treatment
Biophysics
Prefrontal Cortex
Treatment-resistance
Gyrus Cinguli
lcsh:RC321-571
Depressive Disorder, Treatment-Resistant
Neuroimaging
Fluorodeoxyglucose F18
Internal medicine
sgACC
medicine
Humans
lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry
Anterior cingulate cortex
Medicine(all)
Depressive Disorder, Major
Cross-Over Studies
Functional Neuroimaging
General Neuroscience
Unipolar major depression
Middle Aged
medicine.disease
Transcranial Magnetic Stimulation
Antidepressive Agents
CMRglc
Dorsolateral prefrontal cortex
Transcranial magnetic stimulation
Treatment Outcome
medicine.anatomical_structure
Mood disorders
Positron-Emission Tomography
Cardiology
Major depressive disorder
Antidepressant
Female
(18)FDG PET
Neurology (clinical)
HF-rTMS
18FDG PET
Psychology
Treatment-resistant depression
Clinical psychology
Subjects
Details
- ISSN :
- 1935861X
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Brain Stimulation
- Accession number :
- edsair.doi.dedup.....19006907a38cf0bbc77a6ad6e53528a1